|
【结 构 式】 
|
【分子编号】69168 【品名】 【CA登记号】 |
【 分 子 式 】C6H3ClN3.POM 【 分 子 量 】152.563 【元素组成】C 47.24% H 1.98% Cl 23.24% N 27.54% |
合成路线1
该中间体在本合成路线中的序号：(II)N-Protection of 4-chloropyrrolo[2,3-d]pyrimidine (I) with POM-Cl by means of NaH in DME yields the POM-protected deazapurine (II), which is then subjected to Suzuki coupling with pinacol 1-(1-ethoxyethyl)-4-pyrazolylboronate (III) using K2CO3 and Pd(PPh3)4 in BuOH at 82 °C to give the protected pyrazolyl-deazapurine derivative (IV). Without isolation, compound (IV) is N-deprotected with HCl in THF, providing the pyrazole-deazapurine (V), which is then condensed with 2-[1-(ethylsulfonyl)azetidin-3-ylidene]acetonitrile (VI) in the presence of DBU in DMF to produce the 3-[1-(ethylsulfonyl)azetidin-3-yl]pyrazole derivative (VII). Finally, the POM protecting group is removed from precursor (VII) by means of NaOH in MeOH/THF or LiOH·H2O in acetonitrile/i-PrOH .
Coupling of SEM-protected deazapurine (VIII) with azetidine derivative (VI) in the presence of DBU in DMF affords the corresponding ethylsulfonyl derivative (IX), which is then N-deprotected by means of LiBF4 in acetonitrile/water and finally, without isolation, is reacted with NH4OH .
| 【1】 Rodgers, J.D., Shepard, S., Li, Y.-L., Zhou, J., Liu, P., Meloni, D., Xia, M.(Incyte Corp.). Azetidine and cyclobutane derivatives as JAK inhibitors. CN 102026999, EP 2288610, JP 2011514909, KR 2010121657, KR 2012108042, US 2009233903, US 2012077798, US 8158616, US 8420629, US 2013225556, WO 2009114512. |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (I) | 60046 | 4-chloro-7H-pyrrolo[2,3-d]pyrimidine；6-Chloro-7-deazapurine；4-chloropyrrolo[2,3-d]pyrimidine；4-Chloro-1H-pyrrolo[2,3-d]pyrimidine | 3680-69-1 | C6H4ClN3 | 详情 | 详情 |
| (II) | 69168 | C6H3ClN3.POM | 详情 | 详情 | ||
| (III) | 68071 | 1-(1-ethoxyethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole | C13H23BN2O3 | 详情 | 详情 | |
| (V) | 69169 | C9H6N5.POM | 详情 | 详情 | ||
| (VI) | 68070 | 2-[1-(ethylsulfonyl)azetidin-3-ylidene]acetonitrile | C7H10N2O2S | 详情 | 详情 | |
| (VIII) | 68072 | 4-(1H-pyrazol-4-yl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine | C15H21N5OSi | 详情 | 详情 | |
| (IX) | 68073 | 2-(1-(ethylsulfonyl)-3-(4-(7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)azetidin-3-yl)acetonitrile | C22H31N7O3SSi | 详情 | 详情 | |
| (X) | 68074 | 2-(1-(ethylsulfonyl)-3-(4-(7-(hydroxymethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)azetidin-3-yl)acetonitrile | C17H19N7O3S | 详情 | 详情 |
合成路线2
该中间体在本合成路线中的序号：(IIb)N-Protection of 4-chloropyrrolo[2,3-d]pyrimidine (I) with either 2-(trimethylsilyl) ethoxymethyl chloride (SEM-Cl) in DMA or pivaloyloxymethyl chloride (POM-Cl) in THF in the presence of NaH yields the protected deazapurines (IIa) and (IIb) , respectively, which by Suzuki coupling with pinacol 1-(1-ethoxyethyl)-4-pyrazolylboronate (III) by means of Pd(PPh3)4 and K2CO3, followed by acidic hydrolysis of the ethoxyethyl group, affords the respective pyrazolyl deazapurines (Va) and (Vb) . Alternatively, intermediate (Va) can be obtained by Suzuki coupling of deazapurine (IIa) with unprotected pyrazolylboronate (IV) by means of Pd(PPh3)4 and K2CO3 in DMF/H2O at 125 °C . Michael addition of pyrazole derivative (Va) to 3-cyclopentylacrylonitrile (VI) (obtained by Wittig condensation of cyclopentylcarboxaldehyde [VII] with diethyl cyanomethylphosphonate [VIII] by means of t-BuOK in THF) in the presence of DBU in acetonitrile, followed by resolution using chiral preparative HPLC, provides the desired (R)-adduct (IXa) . Alternatively, in an enantioselective procedure, asymmetric aza-Michael reaction of (Va) or (Vb) with (E)-3-cyclopentylacrylaldehyde (X) in the presence of p-nitrobenzoic acid (p-NBA) and a chiral diarylprolinol silyl ether in CHCl3 gives aldehydes (XIa) and (XIb), which by subsequent condensation with NH4OH, followed by oxidation of the intermediate imines with I2 in aqueous solution, leads to the corresponding nitriles (IXa) and (IXb) . Finally, ruxolitinib is obtained by deprotection of compound (IXa) by sequential treatment with LiBF4 in refluxing acetonitrile/H2O followed by aqueous NH4OH , or with TFA in CH2Cl2 and subsequent basification of obtained TFA salt with ethylenediamine (EDA) in MeOH , or by deprotection of compound (IXb) by treatment with NaOH in MeOH/H2O .
In an alternative strategy, ruxolitinib can be directly obtained by Suzuki coupling of unprotected 4-chloropyrrolo[2,3-d]pyrimidine (I) with the pyrazolylboronate (XII) in the presence of Pd(PPh3)4 and K2CO3 in 1,4-dioxane/H2O at 100 °C .
| 【1】 Lin, Q., Meloni, D., Pan, Y. et al. Enantioselective synthesis of Janus kinase inhibitor INCB018424 via an organocatalytic aza-Michael reaction. Org Lett 2009, 11(9): 1999-2002. |
| 【2】 Rodgers, J.D., Shepard, S., Maduskuie, T.P. Jr. et al. (Incyte Corp.). Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors. US 20090181959. |
| 【3】 Rodgers, J.D., Shepard, S., Maduskuie, T.P. Jr. et al. (Incyte Corp.). Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors. CA 2632466, EP 1966202, JP 2009519340, US 2007135461, US 7598257, WO 2007070514. |
| 【4】 Friedman, P.A., Fridman, J.S., Luchi, M.E., Williams, W.V. (Incyte Corp.). Janus kinase inhibitors for treatment of dry eye and other eye related diseases. WO 2010039939. |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (IIa) | 68079 | 4-chloro-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine | C12H18ClN3OSi | 详情 | 详情 | |
| (IIb) | 69168 | C6H3ClN3.POM | 详情 | 详情 | ||
| (Va) | 68072 | 4-(1H-pyrazol-4-yl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine | C15H21N5OSi | 详情 | 详情 | |
| (Vb) | 69169 | C9H6N5.POM | 详情 | 详情 | ||
| (IXa) | 69172 | (R)-3-cyclopentyl-3-(4-(7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)propanenitrile | C23H32N6OSi | 详情 | 详情 | |
| (IXb) | 69175 | C17H17N6.POM | 详情 | 详情 | ||
| (XIa) | 69173 | (R)-3-cyclopentyl-3-(4-(7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)propanal | C23H33N5O2Si | 详情 | 详情 | |
| (XIb) | 69174 | C17H18N5O.POM | 详情 | 详情 | ||
| (I) | 60046 | 4-chloro-7H-pyrrolo[2,3-d]pyrimidine；6-Chloro-7-deazapurine；4-chloropyrrolo[2,3-d]pyrimidine；4-Chloro-1H-pyrrolo[2,3-d]pyrimidine | 3680-69-1 | C6H4ClN3 | 详情 | 详情 |
| (III) | 68071 | 1-(1-ethoxyethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole | C13H23BN2O3 | 详情 | 详情 | |
| (IV) | 68081 | 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole | C9H15BN2O2 | 详情 | 详情 | |
| (VI) | 69170 | cyclopentylcarboxaldehyde;3-cyclopentyl-2-Propenenitrile | 591769-05-0 | C8H11N | 详情 | 详情 |
| (VII) | 69171 | cyclopentylcarboxaldehyde；Cyclopentanecarbaldehyde;Cyclopentanealdehyde;Cyclopentyl aldehyde;Cyclopentylformaldehyde;Formylcyclopentane | 872-53-7 | C6H10O | 详情 | 详情 |
| (VIII) | 10045 | Diethyl cyanomethylphosphonate | 2537-48-6 | C6H12NO3P | 详情 | 详情 |
| (X) | 69176 | (E)-3-cyclopentylacrylaldehyde | C8H12O | 详情 | 详情 | |
| (XII) | 69177 | (S)-3-cyclopentyl-3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)propanenitrile | C17H26BN3O2 | 详情 | 详情 |